Patents by Inventor Mark A. DUERR

Mark A. DUERR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Diagnosis of leukocyte-mediated disease and halogen gas exposure
    Patent number: 10983137
    Abstract: Described are glutathione adducts of fatty aldehydes (FALD-GSH) and methods useful in the detection of FALD-GSH in the identification of pathologies associated with leukocyte-mediated disease conditions, including eosinophil and neutrophil activation. Thus, the present disclosure provides methods of diagnosing a subject as having or being at risk of developing a leukocyte-mediated disease (LMD) comprising (a) detecting the level of glutathione adducts of 2-halofatty aldehydes (FALD-GSH) in a sample; (b) comparing the amount of FALD-GSH with a control or standard reflective of diseased and/or healthy levels of FALD-GSH; and (c) diagnosing the subject as having or being at risk of developing LMD if the level of FALD-GSH in the sample is higher than the control or standard.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: April 20, 2021
    Assignee: Saint Louis University
    Inventors: David A. Ford, Mark A. Duerr
  • DIAGNOSIS OF LEUKOCYTE-MEDIATED DISEASE AND HALOGEN GAS EXPOSURE
    Publication number: 20180003726
    Abstract: Described are glutathione adducts of fatty aldehydes (FALD-GSH) and methods useful in the detection of FALD-GSH in the identification of pathologies associated with leukocyte-mediated disease conditions, including eosinophil and neutrophil activation. Thus, the present disclosure provides methods of diagnosing a subject as having or being at risk of developing a leukocyte-mediated disease (LMD) comprising (a) detecting the level of glutathione adducts of 2-halofatty aldehydes (FALD-GSH) in a sample; (b) comparing the amount of FALD-GSH with a control or standard reflective of diseased and/or healthy levels of FALD-GSH; and (c) diagnosing the subject as having or being at risk of developing LMD if the level of FALD-GSH in the sample is higher than the control or standard.
    Type: Application
    Filed: January 19, 2016
    Publication date: January 4, 2018
    Inventors: David A. FORD, Mark A. DUERR